Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07682376 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
DRUG: Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin

Sponsor

Harbin Medical University

Collaborators

[object Object]
[object Object]
[object Object]